Jack B. Strommen, a director at BioLargo, Inc., has reported a significant acquisition of stock options as part of his compensation package. This transaction, filed on October 2, 2026, is noteworthy as it underscores the ongoing trends in executive compensation within the chemicals and allied products industry.
Strommen's filing reveals that he acquired 187,500 options to purchase common stock at an exercise price of $0.08 per share. This acquisition was made as payment for $15,000 in fees owed to him for his services on the board during the most recently completed quarterly period, in accordance with BioLargo’s 2024 Equity Incentive Plan.
Background
BioLargo, Inc. operates in the chemicals and allied products sector, focusing on innovative industrial applications and services. The company is incorporated in Delaware and has its business address in Westminster, California. BioLargo trades under the ticker symbol BLGO and is registered with the SEC under Central Index Key (CIK) number 0000880242.
What the Filing Says
According to the filing, "This Option was issued to Reporting Person as payment for $15,000 in fees due to Reporting Person by Issuer in exchange for services on its board of directors for the most recently completed quarterly period, pursuant to the Issuer's 2024 Equity Incentive Plan." This highlights the alignment of executive compensation with performance and services rendered.
Impact
This acquisition may affect stakeholders, including shareholders and potential investors, as it reflects the company's approach to compensating its executives. The issuance of stock options is a common practice in the industry, aimed at incentivizing directors and aligning their interests with those of shareholders.
What's Next
The filing does not say what happens next.